{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetic+Change&page=42",
    "query": {
      "condition": "Genetic Change",
      "page": 42
    },
    "page_size": 10
  },
  "pagination": {
    "page": 42,
    "page_size": 10,
    "total_count": 1795,
    "total_pages": 180,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetic+Change&page=43&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetic+Change&page=41&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T07:35:24.856Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01746251",
      "title": "Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Afatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 92,
      "start_date": "2013-01",
      "completion_date": "2021-11",
      "has_results": false,
      "last_update_posted_date": "2020-07-07",
      "last_synced_at": "2026-11-15T07:35:24.856Z",
      "location_count": 4,
      "location_summary": "Palo Alto, California • Boston, Massachusetts • New York, New York",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01746251"
    },
    {
      "nct_id": "NCT02032823",
      "title": "Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 1837,
      "start_date": "2014-04-22",
      "completion_date": "2029-05-28",
      "has_results": true,
      "last_update_posted_date": "2026-07-14",
      "last_synced_at": "2026-11-15T07:35:24.856Z",
      "location_count": 368,
      "location_summary": "Anchorage, Alabama • Anchorage, Alaska • Gilbert, Arizona + 321 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Baldwin Park",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02032823"
    },
    {
      "nct_id": "NCT00389103",
      "title": "Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Smallpox",
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "MVA (smallpox vaccine)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "18 Years to 35 Years"
      },
      "enrollment_count": 0,
      "start_date": "2006-10",
      "completion_date": "2007-01",
      "has_results": false,
      "last_update_posted_date": "2014-01-22",
      "last_synced_at": "2026-11-15T07:35:24.856Z",
      "location_count": 3,
      "location_summary": "Albuquerque, New Mexico • Portland, Oregon • Austin, Texas",
      "locations": [
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00389103"
    },
    {
      "nct_id": "NCT00877773",
      "title": "Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Cancers"
      ],
      "interventions": [
        {
          "name": "Temsirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 44,
      "start_date": "2009-04",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2016-08-25",
      "last_synced_at": "2026-11-15T07:35:24.856Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00877773"
    },
    {
      "nct_id": "NCT04955808",
      "title": "Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery",
      "overall_status": "SUSPENDED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Carcinoma",
        "Colon Carcinoma",
        "Invasive Carcinoma",
        "Kidney Carcinoma",
        "Liver Carcinoma",
        "Malignant Solid Neoplasm",
        "Multiple Myeloma",
        "Prostate Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2400,
      "start_date": "2017-02-07",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-11-15T07:35:24.856Z",
      "location_count": 1,
      "location_summary": "Rockville, Maryland",
      "locations": [
        {
          "city": "Rockville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04955808"
    },
    {
      "nct_id": "NCT00697411",
      "title": "Study of Selected X-Linked Disorders: Aicardi Syndrome",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Aicardi Syndrome",
        "Brain Disorders"
      ],
      "interventions": [
        {
          "name": "Syndrome cause identification",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 500,
      "start_date": "2002-10",
      "completion_date": "2030-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-11-15T07:35:24.856Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00697411"
    },
    {
      "nct_id": "NCT04439357",
      "title": "Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Lymphoma",
        "Advanced Malignant Solid Neoplasm",
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Refractory Lymphoma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Trametinib Dimethyl Sulfoxide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2016-02-25",
      "completion_date": "2027-01-15",
      "has_results": true,
      "last_update_posted_date": "2026-11-13",
      "last_synced_at": "2026-11-15T07:35:24.856Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04439357"
    },
    {
      "nct_id": "NCT00094900",
      "title": "Interleukin-1 Trap to Treat Autoinflammatory Diseases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Inflammation",
        "Familial Mediterranean Fever",
        "Still's Disease, Adult-Onset"
      ],
      "interventions": [
        {
          "name": "IL-1 Trap",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2004-10",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2014-03-04",
      "last_synced_at": "2026-11-15T07:35:24.856Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00094900"
    },
    {
      "nct_id": "NCT03597581",
      "title": "A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gastrointestinal Cancer",
        "Gastrointestinal Neoplasms",
        "Colorectal Cancer",
        "Colorectal Neoplasms",
        "Colorectal Carcinoma",
        "Gastric Cancer",
        "Gastric Neoplasm",
        "KRAS Mutation-Related Tumors",
        "CRC",
        "Colorectal Cancer Metastatic"
      ],
      "interventions": [
        {
          "name": "ompenaclid",
          "type": "DRUG"
        },
        {
          "name": "FOLFIRI",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "FOLFOX regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Inspirna, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 89,
      "start_date": "2018-06-05",
      "completion_date": "2025-03-31",
      "has_results": false,
      "last_update_posted_date": "2025-04-03",
      "last_synced_at": "2026-11-15T07:35:24.856Z",
      "location_count": 17,
      "location_summary": "Prescott Valley, Arizona • Tucson, Arizona • Los Angeles, California + 14 more",
      "locations": [
        {
          "city": "Prescott Valley",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03597581"
    },
    {
      "nct_id": "NCT04265534",
      "title": "KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Non-squamous Non-small-cell Lung Cancer",
        "Non-Squamous Non-Small Cell Neoplasm of Lung",
        "KEAP1 Gene Mutation",
        "NRF2 Gene Mutation",
        "NFE2L2 Gene Mutation"
      ],
      "interventions": [
        {
          "name": "Telaglenastat",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab Immunotherapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Folic acid 400 -1000 μg",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Vitamin B12 1000 μg",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Dexamethasone 4 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Calithera Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2020-07-24",
      "completion_date": "2022-02-09",
      "has_results": false,
      "last_update_posted_date": "2022-09-21",
      "last_synced_at": "2026-11-15T07:35:24.856Z",
      "location_count": 102,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Yuma, Arizona + 86 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04265534"
    }
  ]
}